Back to Search Start Over

Liver-specific overexpression of lipoprotein lipase improves glucose metabolism in high-fat diet-fed mice.

Authors :
Shimizu, Kahori
Nishimuta, Syogo
Fukumura, Yuri
Michinaga, Shotaro
Egusa, Yuka
Hase, Tomomi
Terada, Tomoyuki
Sakurai, Fuminori
Mizuguchi, Hiroyuki
Tomita, Koji
Nishinaka, Toru
Source :
PLoS ONE; 9/13/2022, Vol. 17 Issue 9, p1-14, 14p
Publication Year :
2022

Abstract

The liver is the main organ that regulates lipid and glucose metabolism. Ectopic lipid accumulation in the liver impairs insulin sensitivity and glucose metabolism. Lipoprotein lipase (LPL), mainly expressed in the adipose tissue and muscle, is a key enzyme that regulates lipid metabolism via the hydrolysis of triglyceride in chylomicrons and very-low-density lipoproteins. Here, we aimed to investigate whether the suppression level of hepatic lipid accumulation via overexpression of LPL in mouse liver leads to improved metabolism. To overexpress LPL in the liver, we generated an LPL-expressing adenovirus (Ad) vector using an improved Ad vector that exhibited considerably lower hepatotoxicity (Ad-LPL). C57BL/6 mice were treated with Ad vectors and simultaneously fed a high-fat diet (HFD). Lipid droplet formation in the liver decreased in Ad-LPL-treated mice relative to that in control Ad vector-treated mice. Glucose tolerance and insulin resistance were remarkably improved in Ad-LPL-treated mice compared to those in control Ad vector-treated mice. The expression levels of fatty acid oxidation-related genes, such as peroxisome proliferator-activated receptor α, carnitine palmitoyltransferase 1, and acyl-CoA oxidase 1, were 1.7–2.0-fold higher in Ad-LPL-treated mouse livers than that in control Ad-vector-treated mouse livers. Furthermore, hepatic LPL overexpression partly maintained mitochondrial content in HFD-fed mice. These results indicate that LPL overexpression in the livers of HFD-fed mice attenuates the accumulation of lipid droplets in the liver and improves glucose metabolism. These findings may enable the development of new drugs to treat metabolic syndromes such as type 2 diabetes mellitus and non-alcoholic fatty liver disease. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
19326203
Volume :
17
Issue :
9
Database :
Complementary Index
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
159084337
Full Text :
https://doi.org/10.1371/journal.pone.0274297